PHASE 3 STUDY EVALUATING GENE THERAPY BY TRANSPLANTATION OF AUTOLOGOUS CD34+ STEM CELLS TRANSDUCED EX VIVO WITH THE LENTIGLOBIN BB305 LENTIVIRAL VECTOR IN SUBJECTS WITH SEVERE SICKLE CELL DISEASE

Administered By

Awarded By

Contributors

Start/End

  • April 17, 2020 - March 29, 2022